Cabozantinib and Panitumumab for RAS Wild‐Type Metastatic Colorectal Cancer

LESSONS LEARNED: Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long‐term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Strickler, John H., Rushing, Christel N., Uronis, Hope E., Morse, Michael A., Niedzwiecki, Donna, Blobe, Gerard C., Moyer, Ashley N., Bolch, Emily, Webb, Renee, Haley, Sherri, Hatch, Ace J., Altomare, Ivy P., Sherrill, Gary B., Chang, David Z., Wells, James L., Hsu, S. David, Jia, Jingquan, Zafar, S. Yousuf, Nixon, Andrew B., Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176979/
https://ncbi.nlm.nih.gov/pubmed/33469991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13678
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados